COMMENTARY: Schwartz advances in the Senate to lead the CDC, Trump's third pick

13 votes to 10, or 12 to 10: a vote that can't agree on its own tally

What Reuters reports

According to Reuters, the U.S. Senate's health committee voted Thursday to advance the nomination of Dr. Erica Schwartz to lead the CDC. According to the same source, the nomination was sent to the full Senate by a vote of 13-10, with Democrat Tim Kaine the only member to cross party lines.

What this commentary documents, and what it does not settle

This piece compares several vote counts that do not perfectly align across sources, without claiming to settle which is most accurate. The divergence itself becomes a fact worth commenting on, rather than a detail to silently fix with an arbitrary choice.

A committee vote that cannot even agree on its own score already says a lot about the surrounding confusion.

A committee vote normally serves as a simple factual marker before the full Senate debate, and this counting divergence, however minor, slightly complicates that marker function. This commentary prefers to flag this complication rather than smooth it over artificially to simplify its own account.

The Hill counts differently: 12 votes to 10

A one-vote gap that is not trivial

According to The Hill, the HELP committee advanced Schwartz's nomination by a vote of 12-10, while Sean Kaufman's was sent to the Senate by 12-11. This one-vote gap from Reuters's figure may seem minor, but in an already tight committee vote, every individual vote matters for measuring the real scope of support.

Why this commentary refuses to pick one number over another

Two reputable news agencies that disagree on a committee score reveal a structural limit of real-time coverage of these votes, where first-reported counts can differ slightly from the officially certified final figures. This commentary cites both figures with their respective source, without favoring one over the other.

Thirteen votes or twelve, the committee decided; what remains unclear is the exact number that did it.

Tim Kaine, the sole Democrat to cross the line

A crossing that deserves to be named

According to Reuters, Democrat Tim Kaine was the only member to cross party lines to support Schwartz's nomination. This isolated vote, within an otherwise largely divided confirmation climate, deserves comment for what it reveals about individual motives that can transcend party discipline on certain public health matters.

What this commentary cannot assert about Kaine's motives

No source consulted for this commentary details the precise reasons Tim Kaine gave to justify this isolated vote. This commentary therefore refrains from attributing to him an intention no document explicitly confirms, preferring to name the fact without embroidering the assumed motive.

A single vote that crosses the party line raises a question this commentary cannot resolve.

Trump's third pick for a post already marked by instability

Two precedents withdrawn before a hearing

According to Reuters, Schwartz is President Donald Trump's third candidate to lead the Centers for Disease Control and Prevention. Trump had withdrawn his first CDC pick, Dave Weldon, as well as his first surgeon general nominee, Janette Nesheiwat, in 2025, before either reached a hearing.

What this repeated instability reveals about the difficulty of this file

Three nomination attempts for the same position, two withdrawn before even reaching the hearing stage, outline a pattern of instability that goes beyond Schwartz herself. This pattern deserves comment as a structural fact of this health file, not as a simple administrative coincidence repeated by chance.

Three candidates in a few months to lead the same agency is no longer caution, it is turbulence.

No source consulted explains precisely why Weldon and Nesheiwat were withdrawn before reaching the hearing stage, which limits this commentary's ability to directly compare their respective files with Schwartz's. This documentary gap is named rather than filled with a guess that would exceed what Reuters explicitly reports about these two earlier withdrawals.

Casey Means, the nomination withdrawn for lack of votes

A distinct but revealing precedent

According to Reuters, Trump also withdrew a second surgeon general nominee, Casey Means, in April, when it became apparent she lacked enough votes for confirmation. This withdrawal, explicitly motivated by an insufficient vote count, confirms that the administration closely monitors Senate vote counts before risking a losing vote at a public hearing.

Why this commentary links this precedent to the Schwartz file

An administration that withdraws its candidates rather than risk a public failure apparently judged that Schwartz herself had enough support to be kept on through the committee vote. This implicit political calculation deserves to be named, even though no source confirms it in these explicit terms.

Withdrawing a losing candidate is never an admission of weakness, it is a risk-management calculation.

No source consulted details the exact vote count Means would have faced had her nomination proceeded to a full hearing, which limits this commentary's ability to quantify precisely how close that earlier failure came. What remains documented, regardless of the missing figure, is that the administration chose withdrawal over a public defeat on the record.

Susan Monarez, fired by Kennedy after one month

The heaviest precedent in this file

According to Reuters, if confirmed, Schwartz would be the first permanent CDC director since Susan Monarez, who was fired by Robert F. Kennedy Jr. after less than a month over a conflict on vaccine policy. This precedent, the heaviest of all documented here, shows that holding the CDC directorship guarantees no stability, even once confirmation is secured.

What this quick firing reveals about internal power dynamics

A vaccine policy conflict serious enough to justify a firing after less than a month reveals a deep tension between the agency's scientific direction and the personal positions of its overseeing secretary. This commentary names this tension as a documented fact, without attributing to Kennedy a precise intention beyond what Reuters reports.

One month in office before being fired: the CDC directorship has never seemed as precarious as today.

This commentary treats the Monarez firing as a documented event with a clear timeline, not as evidence for or against either side of the underlying vaccine policy dispute that triggered it.

This commentary does not seek to judge whether the disagreement between Monarez and Kennedy was scientifically sound on either side, a question far beyond the scope of this piece and one that would require epidemiological expertise this commentary does not claim to possess. What is named here is the speed of the firing, a dated, sourced fact, independent of any judgment about its scientific merits.

Kaufman, the controversial nomination advancing in parallel

Two nominations linked in the same committee vote

According to The Hill, the HELP committee sent Sean Kaufman's nomination to the Senate by a vote of 12-11, an even tighter score than Schwartz's. This parallel between two contested health nominations, voted on the same day, illustrates a broader tension running through this administration's health personnel choices, not just the isolated CDC file.

Why this commentary mentions Kaufman without dwelling on it

This commentary focuses on Schwartz's nomination, and mentions Kaufman only to situate the context of the July 30 committee vote, without claiming to analyze in detail the specific motives behind the controversy surrounding his candidacy, which would exceed the scope of this piece.

Two contested nominations voted the same day is no coincidence, it is a day of health tension in the Senate.

A vote postponed the week before, for lack of attendance

What Axios documents about the postponement

According to Axios, the session scheduled the previous week had been postponed because Republicans did not have enough senators present for the vote and because they had more questions about Kaufman. This postponement, driven by a lack of Republican attendance, reveals strained management of the Senate calendar, even within the party in power.

What this postponement reveals about the real priority given to this file

A postponement caused by the absence of senators from the majority itself suggests that this file, despite its evident public health importance, has not always enjoyed maximum logistical priority within the Senate majority. This commentary names this fluctuating priority as a contextual element, without seeing it as proof of deliberate disinterest.

A vote postponed for lack of attendance is never a sign of absolute priority.

No source consulted specifies exactly how many senators were absent that first week, only that the shortfall was sufficient to force a delay, a detail this commentary reports without inflating it into a precise headcount it cannot verify.

This type of postponement linked to Senate absenteeism is not unique to this file: it reflects a broader reality of how American Senate committees function, where lawmakers' busy schedules can delay even votes deemed a priority by the administration in office. This commentary flags this institutional mechanism as useful context, without seeing it as proof of specific disinterest toward Schwartz herself.

The health backdrop: measles, food poisoning, and Ebola

What the sources evoke in the background

The sources consulted for this commentary evoke, in the background, a heavy public health context: the worst measles resurgence in three decades according to Reuters, along with Ebola and Cyclospora outbreaks mentioned by other outlets, without precise numerical cross-referencing in the available excerpts.

Why this commentary refuses to add uncross-checked figures

None of these health tallies are precisely quantified in the sources gathered for this piece, and this commentary refuses to invent a mortality or morbidity statistic that does not explicitly appear in the documents consulted.

Naming a heavy health context never excuses failing to source every figure attached to it.

This commentary would rather leave a sentence without a number than attach a plausible-sounding figure that no consulted document actually states.

This refusal to quantify without proof is not a weakness of this commentary, it is a methodological requirement that distinguishes rigorous opinion journalism from mere anxiety-inducing amplification of a health climate perceived as serious without a solid, independently verifiable numerical basis.

An earlier hearing documented by the French-language press

Zonebourse has followed this file since July

According to Zonebourse, Trump's CDC nominee had already been questioned by the American Senate in mid-July, and an influential senator gave her his support a few days later, boosting her confirmation chances. This French-language coverage, predating the July 30 vote, confirms that this file received enough international attention to justify a first-hand French source rather than a mere translation.

What this earlier record changes in reading the committee vote

Senate support documented as early as mid-July retrospectively clarifies the relatively favorable score Schwartz obtained two weeks later, suggesting this committee vote did not arise from a totally unpredictable balance of power.

Support announced two weeks before the vote is never a scheduling coincidence.

This earlier record documented by Zonebourse does not exempt this commentary from remaining cautious about the exact scope of this prior support, whose full details do not entirely appear in the excerpt consulted for this piece. Reported support never automatically equals a guaranteed vote at the moment of the committee itself.

What this commentary refuses to assert about Kennedy's positions

The acknowledged limits of this judgment

This commentary does not claim to know Robert F. Kennedy Jr.'s exact position on Schwartz's candidacy itself, nor to predict whether she would suffer the same fate as Susan Monarez in the event of a future disagreement on vaccine policy. Both questions remain beyond the reach of the sources gathered for this piece.

What this judgment asserts despite this uncertainty

What this commentary asserts with certainty, however, is that the Monarez precedent structurally weighs on any future nomination to this post, regardless of who holds it. Every confirmed director inherits a climate of prior suspicion that this one precedent alone is enough to install durably.

No nomination is ever confirmed in a vacuum; this one arrives carrying the weight of a still-recent firing.

This weight is not this commentary's invention, nor is it a rhetorical flourish added for dramatic effect; it is a direct consequence of the documented timeline itself, which places one firing and one advancing nomination within the same recent institutional history.

This weight is not hypothetical: it appears explicitly in Reuters's own coverage, which takes care to recall Monarez's fate at the very moment of reporting Schwartz's advance. The reporters themselves establish this link, and this commentary merely follows an association already present in the primary source consulted, without adding a single additional guess of its own.

The loyalty test this vote reveals, beyond the science

A committee vote that exceeds pure health competence

A score of 13-10 or 12-10, depending on the source, with a single party crossing, outlines a vote largely structured by political affiliation rather than by a cross-party scientific consensus on the candidate's qualifications. This divided voting pattern, documented convergently by Reuters and The Hill despite their disagreement on the exact figure, confirms a deep politicization of this type of health nomination.

Why this politicization deserves harsh comment

An agency meant to protect public health apolitically finds itself, through the very mechanics of its confirmation, caught in a partisan power struggle that does not necessarily reflect the candidate's actual scientific qualifications. This holds true regardless of Schwartz's own real professional quality, which this commentary in no way disputes here.

Science should never need a partisan score to be confirmed.

Blunt Rochester had already questioned the nominee in July

Blunt Rochester questions the nominee in July

According to a statement from Senator Blunt Rochester, she directly questioned Trump's nominee during an earlier hearing devoted to her nomination. This hearing, distinct from the July 30 committee vote, allowed a first public examination of Schwartz's positions on sensitive health matters, well before the question of the vote's timing even arose.

What this earlier parliamentary precedent adds to this commentary

A nominee already publicly questioned before her committee vote never arrives before senators as a complete unknown. This commentary notes this earlier step as an additional contextual element, without taking a position on the precise content of the questions posed by the senator herself.

A parliamentary hearing never erases the questions it raised, even weeks later.

This commentary does not have the complete transcript of this earlier hearing, only the fact that it took place and its later favorable outcome for Schwartz. That gap between record and outcome is worth naming rather than papering over with invented detail.

A fragile confirmation for an already fragile agency

This commentary judges that Schwartz's nomination advances within a documented context of institutional instability: two predecessors withdrawn before a hearing, a previous director fired after one month, and a committee vote whose exact score even two serious news agencies dispute. This climate does not disappear with a full Senate confirmation; it will continue to weigh on every future decision by the new director, if she is indeed confirmed.

The Monarez precedent, fired after one month over a vaccine policy disagreement with Robert F. Kennedy Jr., is a reminder that Senate confirmation is never a guarantee of lasting stability at the head of this agency. Nothing in the available sources rules out Schwartz facing a similar fate if a substantive disagreement were to arise with her political oversight.

An agency that lost its director in one month offers no guarantee to the next one.

Conclusion: the real issue goes beyond Schwartz herself

The real question posed by this file is not whether Schwartz is personally qualified to lead the CDC — no source consulted questions her individual competence. The open question is that of institutional stability at an agency that has seen three candidates in a few months and a director fired within four weeks, a turnover rate that undermines the continuity of America's public health response far beyond this single nomination.

Thirteen votes or twelve: whatever the exact figure, this vote mostly confirms an agency still searching for its stability.

No source consulted here predicts what happens next at the CDC, and this commentary makes no attempt to fill that void.

This commentary offers no forecast on the outcome of the final Senate vote, nor on the actual length of Schwartz's tenure if confirmed. What it does retain, however, is that the rapid turnover documented at this post already constitutes, in itself, information about the state of this agency, regardless of who occupies its office in the months ahead.

Sources

Primary sources

Senate HELP Committee — Senate HELP Committee Votes to Approve Trump Admin Nominees

Senate Finance Committee Minority Staff — Report on RFK Jr. Hearing

Senator Blunt Rochester — Senator Blunt Rochester Questions Trump CDC Nominee

Secondary sources

Reuters — US Senate panel votes to advance nomination of Trump CDC pick Schwartz

The Hill — Senate HELP Committee advances Trump's CDC, ASPR, Labor secretary nominees

Axios — Senate panel approves CDC nominee, controversial HHS pick

Zonebourse — La candidate de Trump à la direction des CDC auditionnée

Zonebourse — Le soutien d'un sénateur influent renforce les chances d'Erica Schwartz